MDM2 and cervical cancer: Our current study showed that IU1, a pharmacological deubiquitinating enzyme USP14 selective inhibitor, dramatically decreased MDM2 level, blocked G0/G1 to S phase transition, decreased cell growth and triggered cell apoptosis in cervical cancer cells, suggesting that targeting USP14/MDM2 axis could be a potential strategy for cervical cancer therapy.